Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Angelalign TechnologyFRA:77D -4.90%75 Debt-to-EBITDA is 0.48 as of Dec. 2025, which is 153% above its 10-year median of 0.19. GuruFocus rates FRA:77D with a GF Score™ of 75/100 and a GF Value™ of €12.03 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 469 Medical Devices & Instruments companies, Angelalign Technology ranks better than 71% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Angelalign Technology's Debt-to-EBITDA or its related term are showing as below:
FRA:77D'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.06 Med: 0.19 Max: 0.5
Current: 0.49
During the past 8 years, the highest Debt-to-EBITDA Ratio of Angelalign Technology was 0.50. The lowest was 0.06. And the median was 0.19.
FRA:77D's Debt-to-EBITDA is ranked better than 71% of 469
companies
in the Medical Devices & Instruments industry
Industry Median: 1.62
vs FRA:77D: 0.49
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Angelalign Technology Debt-to-EBITDA Related Terms
Angelalign Technology Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Angelalign Technology's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:77D vs ISRG, BDX, MDLN: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Angelalign Technology's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Angelalign Technology Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Angelalign Technology's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Angelalign Technology's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Angelalign Technology (FRA:77D) has a Debt-to-EBITDA of 0.48 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Angelalign Technology. This is 153% above median its historical median of 0.19. Over the past decade, Angelalign Technology's Debt-to-EBITDA has ranged from 0.06 to 0.50. According to the industry distribution chart, Angelalign Technology ranks #136 out of 469 companies in the Medical Devices & Instruments industry, placing it in the top 29%.
Is Angelalign Technology's Debt-to-EBITDA too high?
Angelalign Technology's current Debt-to-EBITDA of 0.48 is 153% above median its 10-year median of 0.19. Over the past 10 years, this metric has ranged from a low of 0.06 to a high of 0.50. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.62. Angelalign Technology's value of 0.48 is 70.4% below this industry median. Based on the distribution chart, Angelalign Technology ranks #136 out of 469 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Angelalign Technology has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Angelalign Technology's Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Angelalign Technology ranks #136 out of 469 companies for Debt-to-EBITDA. This puts Angelalign Technology in the upper half of its industry. The industry median Debt-to-EBITDA is 1.62. Angelalign Technology's value of 0.48 is 70.4% below this benchmark. Historically, Angelalign Technology's own Debt-to-EBITDA has ranged from 0.06 to 0.50 over the past decade. While the company's 10-year median is 0.19 vs. the industry median of 1.62, Angelalign Technology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.62, based on 469 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Angelalign Technology's current Debt-to-EBITDA of 0.48 is 70.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Angelalign Technology. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Angelalign Technology's current Debt-to-EBITDA is 0.48, which is 153% above median its own 10-year median of 0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Angelalign Technology stock overvalued right now?
Based on GuruFocus' analysis, Angelalign Technology (FRA:77D) is currently considered Modestly Undervalued. The stock's GF Value™ is €12.03, compared to a current price of €9.70 — trading 19.4% below its estimated fair value. The current Debt-to-EBITDA is 0.48, which is 153% above median its 10-year median of 0.19 and 70.4% below the Medical Devices & Instruments industry median of 1.62. Angelalign Technology's overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Angelalign Technology (FRA:77D), the current Debt-to-EBITDA is 0.48 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Angelalign Technology (FRA:77D) Overvalued in 2026?
Based on GuruFocus' analysis, Angelalign Technology stock appears to be undervalued.
The current stock price of €9.70 is trading 19.4% below its estimated GF Value™ of €12.03.
GuruFocus considers Angelalign Technology to be Modestly Undervalued.
Key valuation signals for FRA:77D:
Debt-to-EBITDA: 0.48 (153% above median its 10-year median of 0.19)
GF Value™: €12.03 vs. price of €9.70 (19.4% below fair value)
Industry Position: 70.4% below the Medical Devices & Instruments median (#136 of 469)
No single metric tells the full story. See the FRA:77D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Angelalign Technology Inc is an investment holding company. It is principally engaged in clear aligner treatment solutions, including treatment planning services, manufacturing, and marketing of clear aligners. The company provides dental professionals with self-developed digital orthodontic solutions. The company's Angelalign clear aligner system facilitates dental professionals throughout the entire clear aligner treatment process, including digitally-assisted case assessment support and treatment planning services, provide dental professionals with digitally-assisted case assessment support and treatment planning services, and helps dental professionals design, review, and modify treatment plans.
75GF Score
Get the complete analysis for FRA:77D
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:77D has been successfully added to your 
